Advertisement

Ziopharm Oncology Inc., a New York company with the bulk of its operations in Charlestown, has been given approval from the U.S. Food and Drug Administration to move its melanoma drug candidate into Phase 1 clinical trials, the company announced in a news release.

With the company’s investigational new drug application accepted, Ziopharm said its DNA-based treatment, ZIN ATI-001, is the second cancer drug product stemming from the company’s partnership with synthetic biology firm Intrexon Corp.

SOURCE

Advertisement
Advertisement